FLGT
Fulgent Genetics, Inc.NASDAQHealthcare$16.82+2.31%ClosedMarket Cap: $525.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.47
P/S
1.63
EV/EBITDA
-10.73
DCF Value
$3.26
FCF Yield
-23.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
40.6%
Operating Margin
-28.2%
Net Margin
-18.8%
ROE
-5.4%
ROA
-5.4%
ROIC
-7.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $83.3M | 39.1% | $-36.2M | $-23.4M | $-0.76 | — |
| FY 2025 | $322.7M | 40.6% | $-91.1M | $-60.5M | $-1.97 | — |
| Q3 2025 | $84.1M | 42.2% | $-15.3M | $-6.6M | $-0.21 | — |
| Q2 2025 | $81.8M | 42.1% | $-19.7M | $-19.0M | $-0.61 | — |
| Q1 2025 | $73.5M | 38.6% | $-19.8M | $-11.5M | $-0.37 | — |
| Q4 2024 | $76.2M | 41.8% | $-16.1M | $-5.9M | $-0.19 | — |
| FY 2024 | $283.5M | 37.8% | $-73.9M | $-42.7M | $-1.41 | — |
| Q3 2024 | $71.7M | 37.3% | $-17.1M | $-14.6M | $-0.48 | — |
| Q2 2024 | $71.0M | 37.3% | $-18.9M | $-8.7M | $-0.29 | — |
| Q1 2024 | $64.5M | 34.3% | $-21.8M | $-13.5M | $-0.45 | — |
| Q4 2023 | $70.5M | 35.8% | $-151.1M | $-128.1M | $-4.30 | — |
| FY 2023 | $289.2M | 36.1% | $-195.5M | $-167.8M | $-5.63 | — |